Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing…

Manu Chaudhary, Mohd Amin Mir, Shiekh Gazalla Ayub, for the Protocol 06 Group

In India, elores (CSE-1034: ceftriaxone+sulbactam+disodium edetate) was approved as a broad spectrum antibiotic in year 2011 and is used for management of ESBL/MBL infections in tertiary care centers. The objective of this study was to investigate the efficacy of this drug in patients with ESBL/MBL infections and identify the incidence of adverse events in real clinical settings. This PMS study was conducted at 17 centers across India and included 2500 patients of all age groups suffering from various bacterial infections and treated with CSE-1034. Information regarding demographic, clinical and microbiological parameters, dosage and treatment duration, efficacy and AEs associated with the treatment were recorded. A total of 2500 patients were included in the study and efficacy was evaluated in 2487 patients. In total, 409 AEs were reported in 211 (8.4%) patients. The major AEs reported were vomiting (3.0%), pain at injection site (2.5%), nausea (2.3%), redness at site (1.96%), thrombophlebitis (1.4%). Of total reported AEs, 40 (5.3%) AEs were reported in pediatric, 310 (20.6%) in adult, and 59 (23.6%) in geriatric group. No AE belonging to grade IV or V was reported in any patient. In terms of efficacy, 1977 (79.4%) patients were cured, 501 (20.1%) patients showed clinical improvement and 5 (0.2%) patients were complete failure. The treatment duration varied from 5 to 7 days in different patients depending on the infection type. In this post-marketing surveillance study, CSE-1034 was found to be an effective and safe option in management of patients with multi-drug resistant (MDR) bacterial infections under routine ward settings.